Riversedge Advisors’s AstraZeneca AZN Stock Holding History

Riversedge Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$379K	Buy	2,347 +67	+3%	+$11.2K	0.05%	195
2026 Q2	$432K	Sell	2,280 -483	-17%	-$90.8K	0.06%	142
2026 Q1	$545K	Buy	2,763 +40	+1%	+$7.71K	0.09%	78
2025 Q4	$501K	Buy	2,723 +283	+12%	+$49.6K	0.08%	78
2025 Q3	$374K	Buy	2,440 +411	+20%	+$62.2K	0.06%	97
2025 Q2	$284K	Sell	2,029 -222	-10%	-$31.1K	0.06%	89
2025 Q1	$331K	Buy	+2,251	New	+$326K	0.07%	83

Other funds holding AZN

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $144B AUM 22.91% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $103B AUM 36.66% 1-Year Est. Return

SEB Asset Management Stockholm $27B AUM

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Riversedge Advisors's AZN Position: Q3 2026 in Review

Riversedge Advisors increased its AstraZeneca (AZN) stake by 2.9% in Q3 2026, buying an estimated $11.2K and bringing the position to 2,347 shares worth $379K. The position accounts for 0.05% of the portfolio, ranked #195.

Riversedge Advisors first reported a position in AZN in Q1 2025 and has held it in 7 quarters since. The position peaked at $545K in Q1 2026. 918 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

Riversedge Advisors held 2,347 shares of AstraZeneca worth $379K as of Q3 2026.
Riversedge Advisors bought 67 AstraZeneca shares in Q3 2026, an estimated $11.2K.
AstraZeneca made up 0.05% of Riversedge Advisors's portfolio in Q3 2026, its #195 holding.
Riversedge Advisors first reported a position in AstraZeneca in Q1 2025 and has held it in 7 quarters since.
Riversedge Advisors's AstraZeneca position peaked at $545K in Q1 2026.
918 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Riversedge Advisors's 13F filing for Q3 2026, filed 9 Oct 2026.